simplywall.stJUL 255 min read$ELDN

Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation

Eledon Pharmaceuticals (NASDAQ:ELDN) reported a March 2026 balance sheet (May 2026) with $111m cash and no debt. The company’s cash burn was $69m over the prior year, implying about a 19-month runway. It recorded no revenue and cash burn rose 26%. Cash burn equals about 24% of its $289m market cap.

Original reporting

simplywall.st

Published Jul 25, 2026, 12:16 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Jul 25, 2026, 7:13 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation — source image — Source · simplywall.st

Decision brief

The 30-second read

$ELDNNeutralLow

Why it matters

It concludes the runway is relatively promising but notes cash burn increased 26% over the last year, which could shorten runway and raise the cost of future capital.

Market read

Traders get a risk-focused snapshot of liquidity runway and dilution sensitivity, but no new operational or financing event is disclosed.

What to watch

The article does not provide upcoming catalysts (trial readouts, partnering, or cost-cutting plans) that could change the burn trajectory and financing needs.

Relevance 4/10Novelty 4/10Timing: Post-balance-sheet runway framing after March 2026 cash burn and cash figures (May 2026 report).

Background

The article frames cash burn as negative free cash flow and compares it to cash reserves to estimate runway and dilution risk.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ELDNNeutralMedium confidence

Context

Article estimates Eledon Pharmaceuticals cash runway at about 19 months, using $111m cash and $69m annual cash burn.

Expected impact

Near-term price impact likely limited without a new financing event, but risk premium may rise if burn continues.

Evidence & confidence

The piece is a cash-burn math exercise (runway and dilution sensitivity) rather than a new funding, trial, or regulatory catalyst.

Market effects

Sector

Highlights typical biotech financing risk for pre-revenue companies, reinforcing sector-wide dilution concerns when burn rises.

Regional

No specific regional market linkage beyond US-listed small-cap biotech risk appetite.

Global

Limited; cash-burn runway analysis is company-specific and not tied to global macro or cross-border events.

Counterpoint

What could challenge this read

A longer runway (19 months) can reduce immediate distress risk, so the market may not reprice unless burn accelerates further or financing becomes imminent.

Key entities

company
Eledon Pharmaceuticals
US-listed biotech discussed for cash runway, cash burn, and potential dilution risk.

Read at source ← All news

SEP 3

$ELDNMed

Eledon Advances Tegoprubart In Islet Cell And Kidney Transplant Programs

Eledon Pharmaceuticals (ELDN) submitted an IND application for Tegoprubart in islet cell transplants. Initial studies showed 12 patients achieved insulin independence. The company plans a Phase 3 kidney transplant trial in Q4 2026. ELDN stock closed at $2.99, up 2.34% in pre-market trading.

rttnews.com2 min

AUG 13

$ELDNMed

Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent

Eledon Pharmaceuticals, Inc. (ELDN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights Successful End-of-Phase 2 meeting with FDA supports advancement of tegoprubart into a global Phase 3 kidney transplantation trial, on track to initiate in late 2026 Lo

SEC EDGAR 8-K7 min

JUL 1

$NCELMed

NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes

NewcelX (Nasdaq: NCEL) said it completed a Type B Pre-IND meeting with the FDA for NCEL-101 in type 1 diabetes, with FDA feedback aligning on a regulatory path toward IND-enabling activities and a planned clinical trial. The trial would combine NCEL-101 with Eledon Pharmaceuticals’ (Nasdaq: ELDN) tegoprubart (anti-CD40L).

manilatimes.net3 min

JUN 10

$ELDNMedAI 8/10

Eledon Pharmaceuticals (ELDN) Announces Updated Results From Investigator-Initiated Trial Evaluating tegoprubart

Eledon Pharmaceuticals (ELDN) reported updated investigator-initiated trial results for tegoprubart, an anti-CD40L antibody, in type 1 diabetes patients receiving allogeneic islet cell transplants at the University of Chicago. According to the company, all 12 patients achieved insulin independence, with mean most recent HbA1c ~5.4% and stable graft function over a median 8 months (max 22). No rejection or de novo donor-specific HLA antibodies were reported. Eledon said it will seek FDA regulator

finance.yahoo.com4 min

OCT 31

$AVGOMed

Notable analyst calls this week: Broadcom, Moderna and Abbott among top picks

Analysts made notable calls this week. D.A. Davidson upgraded Broadcom (AVGO) to Buy with a $400 price target, citing AI-related growth prospects. William Blair downgraded Moderna (MRNA) to Market Perform due to valuation concerns. Argus downgraded Abbott (ABT) to Hold after its reduced growth outlook. Jefferies upgraded Rivian (RIVN) to Buy, citing progress in margins and execution. GF Securities raised AMD's (AMD) price target to $720, expecting strong data center growth.

tradingview.com2 min